blenrep gsk fda - Search News

Order byBest matchMost fresh

News

GSK Shares Drop

· 1d · on MSN

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

Continue reading

· 1d · on MSN

GSK Blood Cancer Drug Blenrep Fails to Win FDA Panel Support

GlobalData on MSN · 1d

GSK’s Blenrep faces setback as FDA cancer committee votes against approval

Fierce Pharma1d

FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results